Vertex Pharmaceuticals Total Liabilities & Equity increased by 3.1% to $25.64B in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 13.8%, from $22.53B to $25.64B. Over 5 years (FY 2020 to FY 2025), Total Liabilities & Equity shows an upward trend with a 16.9% CAGR.
An increase typically reflects overall balance sheet growth or expansion of the company's asset base, while a decrease may indicate divestitures or debt repayment.
This represents the sum of all claims against a company's assets, combining obligations to external creditors and the re...
This is a standard accounting identity used across all industries to verify that assets equal the sum of liabilities and equity.
total_liabilities_and_equity| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $12.22B | $12.62B | $13.43B | $14.26B | $15.58B | $16.71B | $18.15B | $18.97B | $20.35B | $21.73B | $22.73B | $23.92B | $20.13B | $22.24B | $22.53B | $22.88B | $24.04B | $24.86B | $25.64B |
| QoQ Change | — | +3.2% | +6.4% | +6.1% | +9.3% | +7.2% | +8.6% | +4.5% | +7.2% | +6.8% | +4.6% | +5.2% | -15.8% | +10.5% | +1.3% | +1.5% | +5.1% | +3.4% | +3.1% |
| YoY Change | — | — | — | — | +27.5% | +32.4% | +35.1% | +33.1% | +30.6% | +30.0% | +25.2% | +26.1% | -1.1% | +2.4% | -0.9% | -4.3% | +19.4% | +11.8% | +13.8% |
We use cookies for analytics. See our Privacy and Cookie Policy.